01. Clinical trials: methodology

P1 The home-based tDCS in MCI and AD comorbid with depression: Behavioral and electrophysiological effects
K. Do Hoon 1, K. Ji Sun 1, K. Han Sol 1, M. Yoo Sun 1
Hallym University College Of Medicine - Chuncheon (Korea, Republic of)

P2 Comparing the Down Syndrome Community Experience with Sporadic AD Participant Insights: Overcoming Barriers to Clinical Trial Recruitment
J. Hendrix 1, P. Ferrell 2, M. Chevrette 1, H. Barce 2, T. Batdorf 2, H. Hillerstrom 1
1Lumind Idsc - Burlington (United States), 2Eli Lilly & Company - Indianapolis (United States)

P3 Key baseline characteristics of participants enrolled using tau PET screening in two phase 2 trials
S. Shcherbinin 1, S. Andersen 1, W. You 1, C. Evans 1, L. Munsie 1, A. Lo 1, J. Sims 1
Eli Lilly And Company - Indianapolis (United States)

P4 First in Human study with ALZ-101, a unique and highly specific therapeutic vaccine against the neurotoxic oligomeric form of Aβ 1-42.
A. Sandberg 1, I. Nylander 1, M. Sheinin 2,3, J. Rinne 2,4,5, Z. Lovro´2, K. Torfgård 1, A. Bylock 1
1Alzinova Ab - Gothenburg (Sweden), 2Crst - Turku (Finland), 3University of Turku, Institute of Biomedicine - Turku (Finland), 4Turku PET centre, University of Turku - Turku (Finland), 5Division of Clinical Neurosciences, Turku University Hospital - Turku (Finland)

P5 Salvaging COVID-19 Interrupted Alzheimer Clinical Trials Using Virtual Patient Simulations
P. Van Der Graaf 1, H. Geerts 2
1Certara - Canterbury (United Kingdom), 2Certara - Berwyn (United States)

P6 Predicting CDR-SB progression using data from 6 interventional clinical trials and ADNI
B. Toth 1, V. Steffen 1, Y. Chen 1, C. Rabe 1, M. Friesenahn 1, T. Bittner 2
1Genentech - South San Francisco (United States), 2Roche - Basel (Switzerland)

P7 Can Pharmacodynamic Interaction With Genotypes and Comedications Explain Variability In Clinical Trials? A Quantitative Systems Analysis
H. Geerts 1, A. Spiros 2
1Certara - Berwyn (United States), 2In Silico Biosciences - Portland (United States)
P8 Finding treatment effects in Alzheimer’s trials in the face of heterogeneity in disease progression
R. Jutten 1, S. Sikkes 2, W. Van Der Flier 2, P. Scheltens 2, P.J. Visser 1, B. Tijms 2
Amsterdam Umc, Location Vumc - Amsterdam (Netherlands)

P9 Analytical validation of APTUS-Aβ assay: an accurate, reproducible and precise LC-MS/MS assay for quantifying plasma amyloid beta 40 and 42
K. Kirmess 1, M. Holubasch 1, S. Knapik 1, M. Meyer 1, J. Contois 1, Y. Hu 1, P. Verghese 1, E. Smith 1, S. Harpstrite 1, T. West 1, I. Fogelman 1, J. Braunstein 1, K. Yarasheski 1
C2n Diagnostics - St Louis (United States)

P10 Reducing sample size requirements for randomized control trials using high-frequency markers
D. Taylor-Rodriguez 1, D. Lovitz 1, N. Mattek 2, C.Y. Wu 2, J. Kaye 2, H. Dodge 2, B. Jedynak 1
1Portland State University - Portland (United States), 2Ohsu - Portland (United States)

P11 Disparities in Alzheimer’s Disease Clinical Trial Enrollment in the United States and Canada: An Indigenous Perspective
N. Olson 1, B. Albensi 1
St Boniface Hospital Research - Winnipeg (Canada)

P12 The Impact of Protocol Design on Data Quality Findings in Dementia Clinical Trials
D. Miller 1, X. Wang 1, A. Kott 2
1Signant Health - Blue Bell (United States), 2Signant Health - Prague (Czech Republic)

P13 Recruitment and Retention in Two Decades of NIH-Funded Alzheimer’s Disease Clinical Trials
M. Ritchie 1, 2, D. Gillen 3, 2, J. Grill 1, 4, 2
1Department Of Neurobiology And Behavior, University Of California, Irvine - Irvine (United States), 2Institute for Memory Impairments and Neurological Disorders, University of California, Irvine - Irvine (United States), 3Department Of Statistics, University Of California, Irvine - Irvine (United States), 4Department of Psychiatry & Human Behavior, University of California, Irvine - Irvine (United States)

P14 Using Digital Twins to Decrease Enrollment and Increase Statistical Power in Alzheimer’s Disease Clinical Trials
D. Hall 1, A. Schuler 1, Y. Poulit 1, D. Bertolini 1, A. Smith 1, C. Fisher 1, J. Walsh 1
Unlearn.ai – San Francisco (United States)

P15 Validation of a novel technology for non-invasive prognosis of amnestic MCI in clinics and clinical trials
K. Vejdani 1, E. Khosravi 1, T. Liebmann 1, P. Krishnamurthy 1, P. Kamali-Zare 1
1 Darmiyan - San Francisco (United States)
02. Clinical trials: results

P16 New Horizons in Alzheimer Research from Amyloid and Beyond
J. Apter 1, R. Iqbal 2, O. Aung 2
1 Global Clinical Trials - Princeton (United States), 2Princeton Medical Institute - Princeton (United States)

P17 Administering tricaprilin after a meal optimises bioavailability and minimises adverse events
J. Walker 1, L. Nelleman 1, L. Chow 1, B. Morimoto 2
1Cerecin - Singapore (Singapore), 2Cerecin - Denver (United States)

P18 Novel formulation AC-SD-03 of tricaprilin leads to excellent PK and safety in doses of up to 30g BID
L. Chow 1, L. Nelleman 1, B. Morimoto 2, J. Walker 1
1Cerecin - Singapore (Singapore), 2Cerecin - Denver (United States)

P19 An evidence-based risk-mitigation approach to study design in APOE4(-) mild to moderate AD
J. Walker 1, L. Nelleman 1, B. Morimoto 2, L. Chow 1
1Cerecin - Singapore (Singapore), 2Cerecin - Denver (United States)

P20 Tricaprilin Shows Similar PK, Safety and Tolerability in Caucasians and Asians
B. Morimoto 1, L. Nelleman 2, L. Chow 2, J. Walker 2
1Cerecin - Denver (United States), 2Cerecin - Singapore (Singapore)

P21 Frequency of Antipsychotic-Associated Adverse Events with Pimavanserin Treatment in Patients with Dementia-related Psychosis
G. Demos 1, E.P. Foff 1, D. Weintraub 2, B. McEvoy 1
1ACADIA Pharmaceuticals, Inc. - Princeton (United States), 2University Of Pennsylvania School Of Medicine - Philadelphia (United States)

P22 The Alzheimer’s disease THErapy with NEuroaid (ATHENE) Study: Assessing the Safety and Efficacy of Neuroaid II (MLC901) in patients with mild to moderate Alzheimer’s disease stable on Cholinesterase inhibitors or Memantine: A 6-month Randomized, double-blind, placebo-controlled trial with a 6-month open label extension: RESULTS
C.L. Chen 1, B.Y. Tan 2, L. Qingshu 3, N. Venketasubramanian 4
1National University Of Singapore - Singapore (Singapore), 2St Luke’s Hospital - Singapore (Singapore), 3Singapore Clinical Research Institute - Singapore (Singapore), 4Raffles Neuroscience Centre - Singapore (Singapore)
**P23** A multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-phospho-tau antibody JNJ-63733657

W. Galpern 1, K. Haeverans 2, L. Janssens 2, G. Triana-Baltzer 3, H. Kolb 3, L. Li 1, P. Nandy 4, M. Mercken 2, K. Van Kolen 2, H. Sun 1, L. Van Nueten 2

1Janssen Research & Development - Titusville (United States), 2Janssen Research & Development - Beerse (Belgium), 3Janssen Research & Development - La Jolla (United States), 4Janssen Research & Development - Raritan (United States)

**P24** The Critical Path for Alzheimer’s Disease (CPAD) – Pre-competitive data sharing and generation of innovative high-impact quantitative tools to support Alzheimer’s disease drug development

S. Sivakumaran 2, K. Romero 1, N. Hanan 1, Y. Karten 1, V. Sinha 2, S. Budd Haeberlein 3, N. Rabbee 4

1Critical Path Institute - Tucson (United States), 2Merck & Co. - Kenilworth (United States), 3Biogen - Cambridge (United States), 4Eisai - Woodcliff Lake (United States)

**P25** Sensory Gamma Stimulation Therapy Reduces Sleep Disruptions in Alzheimer’s Subjects as Assessed by Continuous Actigraphy Recordings

A. Cimenser 1, E. Hempel 1, T. Travers 1, M. Williams 1, M. Hajos 1, Z. Malchano 1

Cognito Therapeutics, Inc - Cambridge (United States)

**03. Clinical trials: imaging**

**P26** Imaging Misfolded Tau in the Retina

U. Kayabasi 1

D-No Visual Therapy Center-Uskudar University - Istanbul (Turkey)

**P27** Molecular Imaging of Tau Pathology in Myotonic Dystrophy Type 1 and Alzheimer’s disease: Implications for Underlying Mechanisms

E. Poulin 1, C. Dallaire-Théroux 2, 3, A.M. Cayer 2, 1, D. Bédard-Tremblay 2, 1, T. Rouleau-Bonenfant 2, 1, F. St-ONGe 4, J.M. Beauregard 5, N. Sergeant 6, J. Puymirat 5, R. Jr. Laforce 2, 3, 1

1Clinique Interdisciplinaire De Mémoire, Département Des Sciences Neurologiques, CHU de Québec - Québec (Canada), 2Université Laval, Faculté De Médecine - Québec (Canada), 3Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec - Québec (Canada), 4Douglas Health Institute - Montréal (Canada), 5Centre De Recherche du CHU de Québec - Québec (Canada), 6Université De Lille, CHRU, Inserm, UMRS 1172, Equipe Alzheimer & Tauopathies - Lille (France)
P28 A Multi-input, Multi-modal Deep Learning Model to Predict Time to Conversion to Alzheimer’s Disease
D. Hibar 1, B. Toth 1, C. Rabe 1, D. Clayton 1
Genentech, Inc - South San Francisco (United States)

P29 Perceptions of Amyloid Imaging Among Cognitively Normal Older Adults with Elevated and Not Elevated Amyloid
M. Ryan 1, 2, D. Gillen 1, 2, J. Grill 1, 3, 4
1Institute For Memory Impairments And Neurological Disorders, University Of California, Irvine - Irvine (United States), 2Department Of Statistics, University Of California, Irvine - Irvine (United States), 3Department of Psychiatry and Human Behavior, University of California, Irvine - Irvine (United States), 4Department of Neurobiology and Behavior, University of California, Irvine - Irvine (United States)

P30 Neuroimaging results of the AMBAR Study, a randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease
1Research & Innovation Unit, Althaia Xarxa Assistencial Universitària De Manresa - Manresa (Spain), 2Department Of Nuclear Medicine, Hospital Universitari Vall D’hebrón, Universitat Autònoma De Barcelona - Barcelona (Spain), 3Alzheimer’s Research Group, Grifols - Barcelona (Spain), 4Research Center And Memory Clinic, Fundació Ace, Institut Català De Neurociències Aplicades-Universitat Internacional De Catalunya - Barcelona (Spain), 5Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, - Madrid (Spain), 6Departments Of Neurology And Psychiatry, University Of Pittsburgh School Of Medicine - Pittsburgh, Pennsylvania (United States)

P31 Greater sleep disturbance is associated with lower myelin content in the cingulum in a cohort enriched for Alzheimer’s disease risk
K.L. Yang 1, D.C. Dean 2, 3, 4, J.M. Oh 1, N. Davenport-Sis 1, D.T. Plante 5, B.A. Riedner 5, S. Asthana 1, 6, 7, S.C. Johnson 1, 6, 7, A. Alexander 3, 4, B.B. Bendlin 1, 6, 7
1Wisconsin Alzheimer’s Disease Research Center, University Of Wisconsin - Madison (United States), 2Department Of Pediatrics, University Of Wisconsin - Madison (United States), 3Department Of Medical Physics, University Of Wisconsin - Madison (United States), 4Waisman Center, University Of Wisconsin - Madison (United States), 5Wisconsin Institute For Sleep And Consciousness, University Of Wisconsin - Madison (United States), 6Wisconsin Alzheimer’s Institute, University Of Wisconsin - Madison (United States), 7Geriatric Research Education and Clinical Center, William S. Middleton Veterans Hospital - Madison (United States)

P32 Cerebellar atrophy can predict conversion of amnestic mild cognitive impairment to dementia in patient with amyloid negative
H.J. Kim 1, S. Lee 1, S. Jo 1, J.H. Lee 2
Department Of Neurology, Asan Medical Center - Seoul (Korea, Republic of)
P33 Early impairment in the ventral visual pathway can predict conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment
H.J. Kim 1, E.N. Cheong 2, S. Jo 1, S. Lee 1, W.H. Shim 3, J.H. Lee 1
1Department Of Neurology, Asan Medical Center, University Of Ulsan College Of Medicine - Songpa-Gu, Seoul (Korea, Republic of), 2Department Of Medical Science And Asan Medical Institute Of Convergence Science And Technology, Asan Medical Center, University Of Ulsan College Of Medicine - Songpa-Gu, Seoul (Korea, Republic of), 3Health Innovation Big Data Center, Asan Institute For Life Sciences, Department Of Radiology And Research Institute Of Radiology, Asan Medical Center, University Of Ulsan College Of Medicine - Songpa-Gu, Seoul (Korea, Republic of)

P34 Prognosis of mild cognitive impairment of uncertain etiology: Assessment and analysis of concordant cases from the IDEAS study
D. Weidman 1, V. Ghisays 1, H. Protas 1, Y. Chen 1, V. Devadas 1, G. Sidarous 1, Y. Su 1
Banner Alzheimer’s Institute - Phoenix (United States)

P35 The effect of cerebral amyloid angiopathy on regional cortical atrophy, independent of cortical amyloid pathology
S. Jo 1, E.N. Cheong 1, H.J. Kim 1, S.J. Lee 1, J.H. Lee 1
Asan Medical Center - Seoul (Korea, Republic of)

P36 [18F]ACI-12589, a novel alpha-synuclein radiotracer as a biomarker in patients with Parkinson’s disease and other synucleinopathies
F. Capotosti 1, E. Vokali 1, J. Molette 1, M. Ravache 1, C. Delgado 1, J. Kocher 1, K. Piorkowska 1, M. Chauhan 1, T. Touilloux 1, H. Kroth 1, R. Luthi-Carter 1, O. Sol 1, A. Pfeifer 1, M. Kosco-Vilbois 1
Ac Immune - Lausanne (Switzerland)
P37 Effect of multidomain interventions on brain functional connectivity of elderly people with spontaneous memory complaint.

L. Perus 1, 2, 3, E. Le Bars 4, J. Deverdun 5, J.F. Mangin 6, A. Gabelle 4
1Memory Resources and Research Center, Montpellier University Hospital, 34 295 Montpellier and Inserm U1061 and University Of Montpellier i-Site Muse - Montpellier (France), 2Institut d'Imagerie Fonctionnelle Humaine, I2FH, Montpellier University Hospital, Montpellier, France. - Montpellier (France), 3Neurospin, CEA, Gif-sur-Yvette, France - Saclay (France), 4Institut D'imagerie Fonctionnelle Humaine, I2fh, Neuroradiology Department, Montpellier University Hospital, Montpellier, France. - Montpellier (France), 5Institut D'imagerie Fonctionnelle Humaine, I2fh, Montpellier University Hospital, Montpellier, France. - Montpellier (France), 6Neurospin, CEA - Gif-Sur-Yvette (France)

04. Clinical trials: biomarkers including plasma

P38 Differentiating amyloid pathology using plasma pyroglutamate-modified amyloid beta assayed with immunomagnetic reduction

S.Y. Yang 1, 2, P.N. Wang 3, K.J. Lin 4
1Magqu Co., Ltd. - New Taipei City (Taiwan), 2MagQu LLC - Surprise (United States), 3Taipei Veterans General Hospital - Taipei (Taiwan), 4Linkou Chang Gung Memorial Hospital - Taipei (Taiwan)

P39 Plasma biomarkers promisingly differentiate Alzheimer's disease, Parkinson's disease and frontotemporal dementia

S.Y. Yang 1
Magqu Co., Ltd. - New Taipei City (Taiwan)

P40 Bio-Hermes: A Biomarker Study Initiated By The Global Alzheimer’s Platform Foundation® To Compare Select Digital and Blood-Based Biomarkers With Clinical Diagnosis and Amyloid-β PET Images

J. Dwyer 1, S. Walsh 1, D. Beauregard 1, E. Gorman 1, J. Bork 1, K. Smith 1, S. Hollingshead 1, R. Mohs 1
Global Alzheimer's Platform Foundation - Washington (United States)

P41 Down Syndrome Associated Alzheimer’s Disease: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study

1Lumind Idsc - Burlington (United States), 2Eli Lilly And Co. - Indianapolis (United States), 3Department of Neurosciences, Alzheimer’s Disease Cooperative Study, University of California San Diego - San Diego (United States), 4National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indiana University School of Medicine - Indianapolis (United States), 5Department of Neurosciences, University of California, San Diego - San Diego (United States)
P42 Studies on the Practical Performance of a Plasma Amyloid β Measurement System by Immunoprecipitation Combined with MALDI-TOF Mass Spectrometry
N. Kaneko 1, Y. Hioki 1,2, R. Yoda 1, A. Korenaga 1, Y. Ohashi 3, M. Honda 3, S. Sekiya 1, S. Iwamoto 1, K. Tsujino 3, K. Tanaka 1
1Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation - Kyoto (Japan), 2Shimadzu Scientific Instruments - Frederick, Md (United States), 3Shimadzu Techno-Research - Kyoto (Japan)

P43 Identification of ADAMTS4 as an Amyloid Precursor Protein Cleaving Enzyme at 669 Site in APP669-711 Production Pathway
T. Tomita 1, M. Matsuzaki 1, N. Kaneko 2, M. Yokoyama 1, Y. Yoshizawa 1, Y. Hioki 2,3, S. Iwamoto 2, K. Tanaka 2
1Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University Of Tokyo - Tokyo (Japan), 2Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation - Kyoto (Japan), 3Shimadzu Scientific Instruments - Frederick, MD (United States)

P44 Identification of prognostic protein biomarkers for cognitive dysfunction in the Origin trial.
S. Hess 1
Sanofi - Frankfurt (Germany)

P45 Deep Proteomic Profiling of AD CSF for Unbiased Biomarker Discovery and Subject Stratification
Y. Feng 1, R. Bruderer 1, D. Heinzmann 1, L. Reiter 1
Biognosys - Schlieren (Switzerland)

P46 Antibody free, Mass Spectrometric procedure for the determination of Aβ40 and Aβ42 in human plasma
L. Sarasa 1, P. Pesini 1, M. Sarasa 1, J.A. Allué 1
Araclon Biotech - Zaragoza (Spain)

P47 Cholesterol and triglyceride levels in Alzheimer’s disease patients undergoing therapeutic plasma exchange with albumin replacement
A.M. Ortiz 1, C. Minguet 1, L. Nuñez 1, A. Ruiz 2,3, O.L. Lopez 4, M. Boada 2,3, A. Páez 1, M. Costa 1
1Alzheimer’s Research Group, Grifols - Barcelona (Spain), 2Research Center and Memory Clinic, Fundació Ace, Institut Català De Neurociències Aplicades-Universitat Internacional De Catalunya - Barcelona (Spain), 3Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III - Madrid (Spain), 4Departments of Neurology and Psychiatry, University of Pittsburgh School of Medicine - Pittsburgh, Pennsylvania (United States)
P48 PK/PD model of the effects of the anti-Sortilin antibody AL001 in humans
M. Ward 1, R. Paul 1, F. Yeh 1, H. Long 1, O. Siddiqui 1, M. Hagay 1, I. Siah 1, T. Schwabe 1, S. Kathman 2, C. Hines 2
1Alector - South San Francisco, CA (United States), 2PPD - Wilmington, NC (United States)

P49 Platelet-miRNAs as biomarkers for dementia with Lewy bodies
A. Gamez-Valero 1, D. Vilas 2, L. Ispierto 2, F. Borras 1, R. Alvarez 1, K. Beyer 1
1Research Institute Germans Trias I Pujol (Spain), 2University Hospital Germans Trias I Pujol (Spain)

P50 Elecsys CSF assays accurately distinguish AD from frontotemporal lobar degeneration
M. Ortner 1, O. Goldhardt 1, J.P. Weinberger 2, F. Müller-Sarnowski 1, J. Diehl-Schmid 1, H. Förstl 1, I. Yakushev 1, T. Grimmer 1
1Department of Psychiatry and Psychotherapy, Klinikum Rechts Der Isar, Technical University of Munich, School of Medicine - Munich (Germany), 2Roche Diagnostics Gmbh - Penzberg (Germany), 3Department of Nuclear Medicine, Klinikum Rechts Der Isar, Technical University of Munich - Munich (Germany)

P51 Using cortical diffusivity analysis to predict progression in early Alzheimer’s Disease
M. Torso 1, I. Hardingham 1, M. Jenkinson 2, S. Chance 1
1Oxford Brain Diagnostics - Oxford (United Kingdom), 2University of Oxford - Oxford (United Kingdom)

P52 Level of neurodegeneration-inducing memory CD8 T cells predicts Alzheimer’s disease and Alzheimer’s-related MCI, and correlates with cognitive decline in banked blood samples from multiple cohorts.
C. Wheeler 1, D. Van Dam 2, Y. Vermeiren 2, H. De Reu 2, V. Van Tendeloo 2, P.P. De Deyn 3, K. Trujillo 2
1T-Neuro Pharma, Inc. - Albuquerque (United States), 2University of Antwerp - Antwerp (Belgium), 3University of Antwerp, University Center Groningen - Groningen (Netherlands)

P53 Transcranial Electromagnetic Treatment (TEMT) Normalizes Plasma Cytokine Levels in Alzheimer’s Patients: Both Immediate and Long-term Immunoregulation
H. Abulaban 1, R. Baranowski 2, X. Lin 3, E. Goodwin 4, B. Gordon 4, A. Gary 4, C. Cao 3
1Axiom Clinical Research of Florida - Tampa (United States), 2Left Coast Engineering - Escondido (United States), 3University of South Florida Taneja College of Pharmacy - Tampa (United States), 4Neuroem Therapeutics, Inc - Phoenix (United States)
05. Clinical trials: cognitive and functional endpoints

P54 The effect of multi-tasking exercise intervention on cognitive function in elderly and cognitive impairment patients: a pilot multicenter study
K.W. Park 1, H.J. Lee 2, H. Park 3
1 Dong-A University College of Medicine - Busan (Korea, Republic of), 2 Busan Metropolitan Dementia Center - Busan (Korea, Republic of), 3 Dong-A University - Busan (Korea, Republic of)

P55 The CITIDEMAGE Study: the role of cholinergic hypothesis and combination therapy in Alzheimer’s disease
P. Gareri 1, A.M. Cotroneo 2, G. Orsitto 3, S. Putignano 4
1 Center For Cognitive Impairment And Dementia - Catanzaro (Italy), 2 Department of Elderly Health Care - Birago Di Vische Hospital And Botticelli Territorial Geriatrics - Turin (Italy), 3 U.o.c. Internal Medicine Ward, P.o. Bari Sud "di Venere", Bari-Azienda Sanitaria Locale Di Bari, Italy - Bari (Italy), 4 Operative Unit Elderly Care, District 30, azienda Sanitaria Locale Di - Naples (Italy)

P56 Exercise and carbohydrate-restricted diet associates with improved insulin resistance and cognitive performance
M.B. Heston 1, 2, J.M. Gaitan 1, Y. Ma 3, B. Derynda 3, S. Lose 1, M.P. Kozuch 1, 4, O.C. Okonkwo 1, K.A. Gretebeck 5, 6, R.J. Gretebeck 5, 7, B.B. Bendlin 1
1 Wisconsin Alzheimer’s Disease Research Center, University Of Wisconsin School Of Medicine And Public Health - Madison (United States), 2 Cellular and Molecular Pathology, University of Wisconsin-Madison - Madison (United States), 3 Nova Southeastern University - Madison (United States), 4 Rollins School of Public Health, Emory University - Atlanta (United States), 5 College Of Nursing, Marquette University - Milwaukee (United States), 6 School of Nursing, University of Wisconsin-Madison - Madison (United States), 7 Department of Exercise and Sport Science, University of Wisconsin-La Crosse - La Crosse (United States)

P57 Real-time capture of gait and actigraphy using industry-grade wearable devices in older adults with and without subjective cognitive decline: Preliminary compliance, sensitivity, and correlations with cognition
A. Atkins 1, W. Horan 1, M. Kraus 1, J. Linthicum 1, R. Keefe 1
Verasci - Durham, NC (United States)

P58 Using speech measures as prognostic markers of rapid cognitive decline: Applications to clinical trial enrichment
K. Mueller 1, R. Koscik 2, S. Hahn 2, G. Stegmann 2, J. Liss 2, V. Berisha 2
1 University of Wisconsin-Madison – Madison, WI (United States), 2 Arizona State University – Tempe, AZ (United States)
06. Cognitive assessment and clinical trials

P59 Generation of an optimized neuropsychological feature set for the quick screening of mild cognitive impairment in clinical settings
M.J. Kleiman 1, J. Galvin 1
University of Miami Miller School Of Medicine - Miami, FL (United States)

P60 Congruence of clinical assessment instruments with online narratives over social media by patients with Alzheimer’s disease and caregivers
A. Tahami 1, Y. Stern 2, S. Doogan 3, Q. Zhang 1
1Eisai, Inc. - Woodcliff Lake (United States), 2Columbia University - New York (United States), 3Real Life Sciences, Inc. - New York (United States)

P61 Remote assessment of speech and language changes in Primary Progressive Aphasia (PPA) and behavioral variant FTD
J. Robin 1, M. Xu 1, L. Kaufman 1, M. Hagey 1, R. Paul 2, O. Siddiqui 2, M. Ward 2, W. Simpson 1, 3
1Winterlight Labs - Toronto (Canada), 2Alector, Inc. - South San Francisco, CA (United States), 3McMaster University - Hamilton (Canada)

P62 Cognitive Reserve, Leisure Activity, and Neuropsychological Profile in the Early Stage of Cognitive Decline
J.M. Kang 1, S.Y. Lee 1, D.J. Kim 1, S.K. Woo 1, J.Y. Lee 2, S.J. Cho 1
1Gil Medical Center, Gachon University College of Medicine - Incheon (Korea, Republic of), 2Seoul National University College of Medicine - Seoul (Korea, Republic of)

P63 Cognitive Profiles of Common Neurological Co-morbidities: A Review of Systematic Reviews
C. Ganzer 1, A. Seifan 2
1Hunter College School of Nursing - New York, NY (United States), 2The Neuro Well Free Corporation - Miami Beach, FL (United States)

P64 Insulin resistance and longitudinal cognition in middle-aged and older adults
G. Ennis 1, E. Jonaitis 2, R. Koscik 1, L. Clark 1, S. Bouges 1, T. James 1, N. Chin 1, C. Engelman 1, R. Anderson 1, S. Asthana 1, S. Johnson 1, B. Bendlin 1
University of Wisconsin-Madison – Madison, WI (United States)

P65 Polygenic Risk for Alzheimer’s Disease Predicts MMSE Decline in Amyloid Positive Older Adults
A. Moore 1, J. Cara 1, L. Schneider 2, A. Torkamani 3, C. Cruchaga 4, J. Collens 1
1Vivid Genomics - San Diego, CA (United States), 2Departments Of Neurology, Psychiatry and Behavioral Sciences, Keck School Of Medicine, University Of Southern California - Los Angeles, CA (United States), 3Scripps Research Translational Institute - La Jolla, CA (United States), 4Knight Alzheimer’s Disease Research Center, Washington University School Of Medicine - St. Louis, MI (United States)
P66 Toward Discriminating Alzheimer’s Disease from Other Dementing Disorders with Modeled Cognitive Processes
J.R. Bock 1, M.D. Lee 2, W.R. Shankle 4, 2, 3, J. Hara 1, 3, D. Fortier 4, T. Mangrola 1
1Medical Care Corporation - Newport Beach, CA (United States), 2Dept. Of Cognitive Sciences, University of California At Irvine – Irvine, CA (United States), 3Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach, CA (United States)

P67 Clinical correlates of types of memory complaints in subjective cognitive decline and amnestic mild cognitive impairment
S.Y. Ryu 1, S.B. Lee 1, T.J. Lee 1, Y.J. Jung 1
The Catholic University of Korea, Daejeon St. Mary’s Hospital - Daejeon (Korea, Republic of)

P68 An Open Standard for Speech Biomarkers to Accelerate Clinical Translation
S. Wallbridge 2, J. Weston 2, R. Lenain 1, A. Shivkumar 1, E. Fristed 1
Novoic - London (United Kingdom)

08. Health economics and clinical trials

P69 Mortality Risk and Use of Long-Term Custodial Care for Patients With Dementia and Psychosis Versus Patients With Dementia Only: A Longitudinal, Matched Cohort Analysis of Medicare Claims Data
N. Rashid 1, J. Wetmore 2, 3, M. Irfan 4, V. Abler 1
1ACADIA Pharmaceuticals, Inc. - San Diego, CA (United States), 2Chronic Disease Research Group – Minneapolis, MN (United States), 3Hennepin County Medical Center – Minneapolis, MN (United States), 4University Of Minnesota And Veterans Affairs Medical Center – Minneapolis, MN (United States)

P70 Estimating progression rates across the spectrum of Alzheimer’s disease for amyloid positive individuals using National Alzheimer’s Coordinating Center data
M. Potashman 1, M. Buessing 2, M. Levitchi Benea 1, J. Cummings 3, 4, S. Borson 5, P. Pemberton Ross 6, A.J. Epstein 2
1Biogen – Cambridge, MA (United States), 2Medicus Economics – Boston, MA (United States), 3Chambers-Grundy Center For Transformative Neuroscience Unlv - Las Vegas, NV(United States), 4Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas, NV(United States), 5University Of Washington – Seattle, WA (United States), 6Biogen - Baar (Switzerland)
P71 Comparative efficacy, safety, tolerability, and effectiveness of antipsychotics in the treatment of dementia related psychosis (DRP): A systematic literature review
I. Yunusa 1, N. Rashid 2, S. Chaugule 1, V. Abler 2, K. Rajagopalan 1
1An-L-It-Iks, Inc – Boston, MA (United States), 2Acadia Pharmaceuticals, Inc - San Diego, CA (United States)

P72 Caregiver perspectives on the burden and impact of agitation in caring for loved ones with Dementia/Alzheimer’s disease: A collaboration with UsAgainstAlzheimer’s A-LIST®
M. Sanon Aigbogun 1, M. Cloutier 2, E. Serra 2, T. Frangiosa 3, V. Biggar 3, R. Baker 1, M. Michael 4, H. Gandhi 1, M. Gauthier-Loiselle 2
1Otsuka Pharmaceutical Development & Commercialization, Inc. – Princeton, NJ (United States), 2Analysis Group, Inc. - Montreal (Canada), 3Usagainst Alzheimer’s – Washington, DC (United States), 4Otsuka America Pharmaceutical, Inc. – Princeton, NJ (United States)

09. Epidemiology and clinical trials

P73 Risk of Developing Epilepsy in Alzheimer’s Disease Patients
J.H. Lee 2
National Health Insurance Service Ilsan Hospital - Goyang-Si (Korea, Republic of)

P74 Relationship between genetic variants of ACAT1 and APOE with the susceptibility to dementia (SADEM study)
T. Juarez-Cedillo 1, J.S. Alavez Rubio 1, J. Escobedo De La Peña 1
Instituto Mexicano Del Seguro Social - México (Mexico)

P75 Comparing Alzheimer’s disease (AD) progression in Alzheimer’s Disease Neuroimaging Institute (ADNI) subjects with mild cognitive impairment (MCI) to progression observed in the SCarlet RoAD clinical trial
S. Yiu 3, F. Model 2, L. Butler 2, C. Gower-Page 1, X. Teitsma 2, P. Delmar 2
3Roche Products Limited - Welwyn Garden City (United Kingdom), 2F. Hoffmann-La Roche Ltd - Basel (Switzerland)

11. New therapies and clinical trials

P76 Impact of pimavanserin treatment on motor function in patients with neurodegenerative disease: results from 3 clinical studies
D. Weintraub 1, E.P. Foff 2, C. Ballard 3, B. McEvoy 2, B. Coate 2, G. Demos 2, A. Berrio 2, B. Abbs 2, J.M. Youakim 2, S. Stankovic 2
1Departments Of Psychiatry And Neurology, Perelman School Of Medicine At The University Of Pennsylvania - Philadelphia (United States), 2ACADIA Pharmaceuticals, Inc - Princeton (United States), 3University Of Exeter Medical School, Exeter - Exeter (United Kingdom)
P77 A phase 2a, open-label multicenter study to evaluate the safety and tolerability of repeated intrathecal administration of NurOwn® (autologous mesenchymal stem cells secreting neurotrophic factors) in patients with prodromal to mild Alzheimer’s Disease

B. Dubois 1, R. Kern 2, S. Ward 2, S. Lindborg 2, C. Lebovits 2, P. Scheltens 3

1Salpétrière University Hospital - Paris (France), 2Brainstorm Cell Therapeutics - New York (United States), 3Amsterdam Umc - Amsterdam (Netherlands)

P78 The epigenetic BET protein inhibitor apabetalone counters brain endothelial activation and monocyte adhesion

E. Kulikowski 1, S. Wasiak 1, L. Fu 1, E. Daze 1, D. Gilham 1, B. Rakai 1, S. Stotz 1, L. Tsujikawa 1, C. Sarsons 1, D. Studer 2, K. Rinker 2, R. Jahagirdar 1, N. Wong 1, M. Sweeney 1, J. Johansson 2

1Resverlogix Corp - Calgary (Canada), 2University Of Calgary - Calgary (Canada)

P79 ACD856, a novel cognitive enhancer targeting neurotrophin signaling for the treatment of Alzheimer’s Disease

P. Forsell 1, G. Nordvall 1, M. Halldin 1, M. Dahlström 1, N. Madjid 1, M. Rother 1, A. Van Es Johansson 1, J. Lundkvist 2, M. Eriksdotter 2, 3, M. Jönsson 1, B. Winblad 2, 3, J. Sandin 4

1Alzecure Pharma Ab - Huddinge (Sweden), 2Dept of Neurobiology, Care Sciences And Society, Karolinska Institutet - Stockholm (Sweden), 3Dept Geriatric Medicine, Karolinska University Hospital - Huddinge (Sweden)

P80 Development of a Dual Aβ-Tau Vaccine for the Prevention and Treatment of Alzheimer’s Disease

R. Barbour 1, F. Bard 1, A. Elmaarouf 1, H. Prill 1, K. Thomas 1, G. Kinney 1, W. Zago 1

Prothena Biosciences Inc - South San Francisco, CA (United States)


M. Skov 1, R. Barbour 1, P. Dolan 1, A. Elmaarouf 1, E. Goldbach 1, M. Holden 1, L. Li 1, T. Nijjar 1, H. Prill 1, J. Salmans 1, K. Thomas 1, S. Tam 1, C. Tourino 1, F. Bard 1, G. Kinney 1, W. Zago 1

Prothena Biosciences Inc - South San Francisco, CA (United States)

P82 gamma-Secretase modulators show selectivity for gamma-secretase-mediated amyloid precursor protein intramembrane processing

J. Lundkvist 1, 2, T. Weber 3, 2, J. Wanngren 2, H. Kvartsberg 4, 5, P. Larssen 2, 6, D. Wu 2, 7, D. Oliveira 2, J. Sandin 1, 2, H. Zetterberg 4, 5, 8, K. Blennow 4, 5, G. Nordvall 1, 2, B. Winblad 2, E. Portelius 4, 5, H. Karlström 2

1Alzecure Pharma - Stockholm (Sweden), 2Department Of Neurobiology, Care And Society, Karolinska Institutet - Solna (Sweden), 3Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At The University Of Gothenburg - Gothenburg (Sweden), 4Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), 5Mabtech AB - Stockholm (Sweden), 6Department of Obstetrics and Gynecology, First Affiliated Hospital of Nanjing Medical University
Medical University, Nanjing, Jiangsu - Nanjing (China), 8Department of Neurodegenerative Disease, UCL Institute of Neurology - London (United Kingdom)

P83 Predicting Response to Virtual Reality Therapy for Treatment of BPSD in Acute-care Settings
1York University - Toronto (Canada), 2University Of Toronto - Toronto (Canada), 3Uhn - Toronto (Canada)

P84 Administering Virtual Reality Therapy to Manage Behavioural and Psychological Symptoms in Patients with Dementia Admitted to an Acute-care Hospital: Results of a Pilot Study
1York University - Toronto (Canada), 2Uhn - Toronto (Canada), 3York U - Toronto (Canada), 4Mgh - Toronto (Canada)

P85 Introducing Virtual Reality therapy for inpatients with dementia admitted to an acute-care hospital: Learnings from a pilot to pave the way to a randomized controlled trial.
L. Appel 1, E. Kisonas 2, E. Appel 2, J. Klein 3, D. Bartlett 3, J. Rosenberg 4, C. Smith 4
1York University - Toronto (Canada), 2Uhn - Toronto (Canada), 3York U - Toronto (Canada), 4Mgh - Toronto (Canada)

P86 Non-invasive gamma sensory stimulation for the treatment of Alzheimer’s disease: interim safety and feasibility from multiple prospective clinical studies evaluating long-term, home use
Z. Malchano 1, E. Hempel 1, A. Boasso 1, N. Myrthil 1, K. Martin 1, N. Strozewski 1, T. Travers 1, K. Kwan 1, C. Cotter 1, M. Williams 1, A. Cimenser 1, M. Hajos 1
Cognito Therapeutics – Cambridge, MA (United States)

12. Proof of concept/translational research in AD

P87 Allele specific knockdown of APOE e4 expression: A novel platform for precision gene therapy in Alzheimer’s disease
O. Chiba-Falek 1, B. Kantor 1
Duke University – Durham, NC (United States)

P88 Voluntary Running Enhances Hippocampal Proliferation by Increasing Hippocampal Neurotrophic Factors
X. Bo 1
School of Physical Education & Health Care, East China Normal University - Shanghai (China)
P89 Effects of THN201, a combination of donepezil and low dose mefloquine, on cognition and quantitative EEG in healthy subjects during a scopolamine challenge
1Lille University - Lille (France), 2Marseille University - Marseille (France), 3Grenoble University - Grenoble (France), 4Bordeaux University - Bordeaux (France), 5Clermont-Ferrand University - Clermont-Ferrand (France), 6Toulouse University - Toulouse (France), 7Theranexus - Fontenay Aux Roses (France)

P90 Reduced non-fibrillar Aβ species in a patient treated with low doses of BACE1 inhibitor
1Memory Unit, Department of Neurology, Institut D’investigacions Biomèdiques Sant Pau-Hospital De Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. - Barcelona (Spain), 2Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. - Madrid (Spain), 3Neurological Tissue Bank Of The Biobanc-Hospital Clinic-Idibaps, Barcelona Spain. - Barcelona (Spain), 4Alzheimer’s disease and other cognitive disorders unit. Neurology Service, Hospital Clínic de Barcelona-IDIBAPS, Barcelona Spain - Barcelona (Spain)

P91 Translation of RG6102, an amyloid-targeting therapy Brain Shuttle construct with superior brain penetration properties, to the clinic
F. Hoffmann-La Roche Ltd - Basel (Switzerland)

P92 Independent validation of EuroPOND Alzheimer’s disease staging model on real-world clinical data
1Dep. Of Biomedical Sciences, Institute Born-Bunge, University Of Antwerp - Antwerpen (Belgium), 2icometrix - Leuven (Belgium), 3Centre For Medical Image Computing, Department Of Computer Science, U C L - London (United Kingdom), 4Dep. of Neurology and Center for Neurosciences, UZ Brussel and Vrije Universiteit Brussel (VUB) - Jette (Belgium)

P93 Care partner outcomes associated with perceived relationship closeness between care partners and care recipients
C.L. Kew, A. Khera, C. Supnet, B. Kelley, S.B. Juengst
Ut Southwestern Medical Center – Dallas, TX (United States)
P94 Quantitative Systems Pharmacology model of tau spreading in AD to enable the development of anti-tau therapies
L. Wille 1, J. Grant 1, S. Iadevaia 2, H. Abdul 1, K. Madrasi 1, A. Simen 2, A.J. Schwarz 2, M. Quinton 2, H. Faessel 2, F. Hua 1, J. Apgar 1, J. Burke 1, M. Vakilynejad 2
1Applied Biomath – Concord, MA (United States), 2Takeda – Cambridge, MA (United States)

P95 Investigating the Global Proteomic Impact and Translational Implications of Tolfenamic Acid Treatment
J. Hill 1, N. Zawia 1, 2, 3
1Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island – Kingston, RI (United States), 2Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, RI (United States), 3George and Anne Ryan Institute for Neuroscience, University of Rhode Island – Kingston, RI (United States)

P96 The lack of c-Abl improves behavioral performance in an animal model of Alzheimer’s disease
A. Alvarez 1, R. León 1, C. Riquelme 1, S. Zanlungo 2, A. Dulcey 3, J. Marugan 3
1Cell Signaling Laboratory, Department of Cell and Molecular Biology, Biological Sciences Faculty, Care-Uc, P. Universidad Catolica De Chile. - Santiago (Chile), 2Gastroenterology Department, School of Medicine, P. Universidad Catolica De Chile - Santiago (Chile), 3Ncats-NIH Chemical Genomic Center – Bethesda, MD (United States)

13. Digital health/E-trials

P97 Evaluation of speech-based digital biomarkers for Alzheimer’s disease
J. Robin 1, L. Kaufman 1, W. Simpson 1, 2
1Winterlight Labs - Toronto (Canada), 2McMaster University - Hamilton (Canada)

P98 Developing and assessing a digitally supported care management programme for caregivers of people with dementia: A cluster-randomised controlled trial (GAIN)
O.A. Klein 1, J.R. Thryian 2, M. Boekholt 2, D. Afrin 2, C. Dornquast 2, M. Lindner 2, B. Michalowsky 2, I. Zwingmann 3, A. Dreier-Wolfgramm 4, S. Teipel 1, W. Hoffmann 2, I. Kilimann 1
1German Center For Neurodegenerative Diseases - Rostock (Germany), 2German Center For Neurodegenerative Diseases - Greifswald (Germany), 3European University Of Applied Sciences - Rostock (Germany), 4Hamburg University Of Applied Sciences - Hamburg (Germany)

P99 Validating virtual tools for remote sampling of neurological function: comparing task-driven EEG in the lab and in the home
B. Murphy 1, F. Barbey 1, A. Buick 2, J. Dyer 1, H. Nolan 1
1Brainwavebank Ltd. - Dublin (Ireland), 2Brainwavebank Ltd. - Belfast (United Kingdom)
P100 Automated administration of Serial Subtraction in a remote data collection context: novel timing features related to task difficulty and participant demographics.
N. Taptiklis 1, B. Jennifer 1, 2, F. Francesca 1, 2
1Cambridge Cognition - Cambridge (United Kingdom), 2Dept. Psychiatry, University of Cambridge - Cambridge (United Kingdom)

14. Telemedicine and AD clinical trials

L. Zisko 1, C. Cordell 1, J. Smith 1, J. Trotter 1, L. Thurman 1, J. Sipchen 1
Global Alzheimer's Platform Foundation (gap) - Washington (United States)